Mark Genovese (Stanford via Twitter)
Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases
With an FDA OK for the use of filgotinib in rheumatoid arthritis expected to drop weeks from now, Gilead has recruited a new leader from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
